171 related articles for article (PubMed ID: 21035354)
1. VEGF targeted therapy in acute myeloid leukemia.
Rodriguez-Ariza A; Lopez-Pedrera C; Aranda E; Barbarroja N
Crit Rev Oncol Hematol; 2011 Nov; 80(2):241-56. PubMed ID: 21035354
[TBL] [Abstract][Full Text] [Related]
2. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
Song G; Li Y; Jiang G
Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
[TBL] [Abstract][Full Text] [Related]
3. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
4. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies.
Reichert F; Barak V; Tarshis M; Prindull G; Tarshis E; Ben-Ishay Z
Eur J Haematol; 2005 Jul; 75(1):41-6. PubMed ID: 15946309
[TBL] [Abstract][Full Text] [Related]
6. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
7. [Change of vascular endothelial growth factor and its receptors expression in acute myeloid leukemia before and after treatment].
Zhang JQ; Wang JK; Li YM
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):100-2. PubMed ID: 14990052
[TBL] [Abstract][Full Text] [Related]
8. Role of angiogenesis inhibitors in acute myeloid leukemia.
Fiedler W; Staib P; Kuse R; Dührsen U; Flasshove M; Cavalli F; Hossfeld DK; Berdel WE
Cancer J; 2001; 7 Suppl 3():S129-33. PubMed ID: 11779083
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic therapy against gastrointestinal tract cancers.
Iwasaki J; Nihira S
Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
[TBL] [Abstract][Full Text] [Related]
11. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
[TBL] [Abstract][Full Text] [Related]
12. Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels.
Glenjen NI; Hatfield K; Bruserud Ø
Eur J Haematol; 2005 Jan; 74(1):24-34. PubMed ID: 15613103
[TBL] [Abstract][Full Text] [Related]
13. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
Ellis LM; Hicklin DJ
Clin Cancer Res; 2008 Oct; 14(20):6371-5. PubMed ID: 18927275
[TBL] [Abstract][Full Text] [Related]
14. Retinal anti-angiogenesis by a new route.
Bicknell R
Nat Biotechnol; 2008 May; 26(5):528-9. PubMed ID: 18464784
[No Abstract] [Full Text] [Related]
15. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis--a possible target for novel therapies?
Canavese M; Altruda F; Ruzicka T; Schauber J
J Dermatol Sci; 2010 Jun; 58(3):171-6. PubMed ID: 20430590
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
Tie J; Desai J
Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumor angiogenesis.
Gaur P; Bose D; Samuel S; Ellis LM
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S12-9. PubMed ID: 19393831
[TBL] [Abstract][Full Text] [Related]
19. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells.
Böhm A; Aichberger KJ; Mayerhofer M; Herrmann H; Florian S; Krauth MT; Derdak S; Samorapoompichit P; Sonneck K; Vales A; Gleixner KV; Pickl WF; Sperr WR; Valent P
Eur J Clin Invest; 2009 May; 39(5):395-405. PubMed ID: 19320940
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic phytochemicals and medicinal herbs.
Jeong SJ; Koh W; Lee EO; Lee HJ; Lee HJ; Bae H; Lü J; Kim SH
Phytother Res; 2011 Jan; 25(1):1-10. PubMed ID: 20564543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
